Trials / Completed
CompletedNCT04643093
Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Orient Pharma Co., Ltd.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 390 (actual)
- Sponsor
- Orient Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate whether the efficacy of 1PC111 is superior to pitavastatin and ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia in the 12 week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pitavastatin | Pitavastatin, QD |
| DRUG | Ezetimibe | Ezetimibe, QD |
| DRUG | 1PC111 | 1PC111, QD |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-08-19
- Completion
- 2021-10-05
- First posted
- 2020-11-24
- Last updated
- 2022-05-18
Locations
34 sites across 3 countries: Australia, New Zealand, Taiwan
Source: ClinicalTrials.gov record NCT04643093. Inclusion in this directory is not an endorsement.